|
TABLE OF CONTENTS
| | | | Volume 7, June 2017 | | In this issue Review Original Articles Letters to the Editor | | | | | Review | Top | | Acute lymphoblastic leukemia: a comprehensive review and 2017 updateT Terwilliger and M Abdul-Hay Blood Cancer J 2017 7: e577; 10.1038/bcj.2017.53 Abstract | Full Text | | Original Articles | Top | | Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomibE Kastritis, M Gavriatopoulou, M Roussou, D Fotiou, D C Ziogas, M Migkou, E Eleutherakis-Papaiakovou, I Panagiotidis, N Kanellias, E Psimenou, E Papadopoulou, C Pamboucas, E Manios, H Gakiopoulou, A Ntalianis, A Tasidou, S Giannouli, E Terpos and M A Dimopoulos Blood Cancer J 2017 7: e570; 10.1038/bcj.2017.47 Abstract | Full Text | | | | A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myelomaA K Mitra, T Harding, U K Mukherjee, J S Jang, Y Li, R HongZheng, J Jen, P Sonneveld, S Kumar, W M Kuehl, V Rajkumar and B Van Ness Blood Cancer J 2017 7: e581; 10.1038/bcj.2017.56 Abstract | Full Text | | | | Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myelomaP Ravi, S Kumar, W Gonsalves, F Buadi, M Q Lacy, R S Go, A Dispenzieri, P Kapoor, J A Lust, D Dingli, Y Lin, S J Russell, N Leung, M A Gertz, R A Kyle, P L Bergsagel and S V Rajkumar Blood Cancer J 2017 7: e569; 10.1038/bcj.2017.46 Abstract | Full Text | | | | CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remissionL H Xie, M Biondo, S J Busfield, A Arruda, X Yang, G Vairo and M D Minden Blood Cancer J 2017 7: e567; 10.1038/bcj.2017.52 Abstract | Full Text | | | | The thrombopoietin/MPL axis is activated in the Gata1 low mouse model of myelofibrosis and is associated with a defective RPS14 signatureM Zingariello, L Sancillo, F Martelli, F Ciaffoni, M Marra, L Varricchio, R A Rana, C Zhao, J D Crispino and A R Migliaccio Blood Cancer J 2017 7: e572; 10.1038/bcj.2017.51 Abstract | Full Text | | Letters to the Editor | Top | | Systematic comparison of donor chimerism in peripheral blood and bone marrow after hematopoietic stem cell transplantationC Bach, M Steffen, W Roesler, J Winkler, A Mackensen, K-D Stachel, M Metzler and B M Spriewald Blood Cancer J 2017 7: e566; 10.1038/bcj.2017.42 Full Text | | | | Evaluation of coagulopathy before and during induction chemotherapy for acute lymphoblastic leukaemia, including assessment of global clotting testsK Burley, J Salem, T Phillips, C Reilly-Stitt, D I Marks, O Tunstall, J Moppett, A Mumford and C A Bradbury Blood Cancer J 2017 7: e574; 10.1038/bcj.2017.54 Full Text | | | | CD27 expression and its association with clinical outcome in children and adults with pro-B acute lymphoblastic leukemiaD Chen, N Gerasimčik, A Camponeschi, Y Tan, Q Wu, S Brynjolfsson, J Zheng, J Abrahamsson, J Nordlund, G Lönnerholm, L Fogelstrand and I-L Mårtensson Blood Cancer J 2017 7: e575; 10.1038/bcj.2017.55 Full Text | | | | Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefitM A Dimopoulos, M Roussou, M Gavriatopoulou, D Fotiou, D C Ziogas, M Migkou, I Panagiotidis, E Eleutherakis-Papaiakovou, N Kanellias, E Psimenou, S Marinaki, D Bacharaki, D Mparmparoussi, C Matsouka, S Giannouli, E Terpos and E Kastritis Blood Cancer J 2017 7: e571; 10.1038/bcj.2017.49 Full Text | | | | Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myelomaT Dosani, F Covut, R Beck, J J Driscoll, M de Lima and E Malek Blood Cancer J 2017 7: e579; 10.1038/bcj.2017.60 Full Text | | | | Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trialM Hunault-Berger, N Maillard, C Himberlin, C Recher, A Schmidt-Tanguy, B Choufi, C Bonmati, M Carré, M-A Couturier, E Daguindau, J-P Marolleau, F Orsini-Piocelle, J Delaunay, E Tavernier, S Lissandre, M Ojeda-Uribe, L Sanhes, L Sutton, A Banos, L M Fornecker, M Bernard, D Bouscary, A Saad, M Puyade, V Rouillé, I Luquet, M C Béné, J-F Hamel, F Dreyfus, N Ifrah and A Pigneux for the FILO Group Blood Cancer J 2017 7: e568; 10.1038/bcj.2017.50 Full Text | | | | VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimensL Lopes-Aguiar, M T Delamain, A B C Brito, G J Lourenço, E F D Costa, G B Oliveira, J Vassallo, C A De Souza and C S P Lima Blood Cancer J 2017 7: e580; 10.1038/bcj.2017.58 Abstract | Full Text | | | | Cryptic t(3;8)(q27;q24) and/or MYC-BCL6 linkage associated with MYC expression by immunohistochemistry is frequent in multiple-hit B-cell lymphomasH Ohno, M Nakagawa, C Kishimori, K Fukutsuka and G Honjo Blood Cancer J 2017 7: e578; 10.1038/bcj.2017.59 Full Text | | | | Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approachM Went, A Sud, P J Law, D C Johnson, N Weinhold, A Försti, M van Duin, J S Mitchell, B Chen, R Kuiper, O W Stephens, U Bertsch, C Campo, H Einsele, W M Gregory, M Henrion, J Hillengass, P Hoffmann, G H Jackson, O Lenive, J Nickel, M M Nöthen, M I da Silva Filho, H Thomsen, B A Walker, A Broyl, F E Davies, C Langer, M Hansson, M Kaiser, P Sonneveld, H Goldschmidt, K Hemminki, B Nilsson, G J Morgan and R S Houlston Blood Cancer J 2017 7: e573; 10.1038/bcj.2017.48 Full Text | | | | High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)T E Witzig, B LaPlant, T M Habermann, E McPhail, D J Inwards, I N Micallef, J P Colgan, G S Nowakowski, S M Ansell and P B Johnston Blood Cancer J 2017 7: e576; 10.1038/bcj.2017.57 Full Text | | | | | You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved. | | | | |
No comments:
Post a Comment